Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 114

Drug Profile

V 114

Alternative Names: MK-V114; PCV-15; Pneumococcal vaccine conjugate 15 valent; Pneumococcal vaccine conjugate 15 valent - Merck; V114; V114 aluminum-adjuvanted

Latest Information Update: 01 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Conjugate vaccines; Pneumococcal vaccines; Polysaccharides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Pneumococcal infections

Most Recent Events

  • 30 Jan 2019 V 114 receives Breakthrough Therapy status for Pneumococcal infections (In infants, In children, In adolescents) in USA
  • 14 Dec 2018 Merck Sharp & Dohme initiates the phase III PNEU-LINK trial for Pneumococcal infections (In infants, Prevention) (IM) (NCT03692871)
  • 20 Nov 2018 Merck Sharp & Dohme plans the phase III V114-031/PNEU-LINK trial for Pneumococcal infections (In infants, Prevention) (IM) (NCT03692871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top